5-AIQ
5-AIQ (5-Aminoisoquinolin-1-one) is a PARP-1 inhibitor. 5-AIQ is an important functional group in various drugs. 5-AIQ reduces the tissue injury associated with ischemia-reperfusion of the liver, it can be used for the research of the research conditions associated with ischemia-reperfusion of the liver[1][2].
Product Specifications
CAS Number
93117-08-9
Product Name Alternative
5-Aminoisoquinolin-1-one
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
PARP
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; Epigenetics
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/5-aiq.html
Purity
99.75
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C1NC=CC2=C1C=CC=C2N
Molecular Formula
C9H8N2O
Molecular Weight
160.18
Precautions
H302, H315, H319, H335
References & Citations
[1]Vinod KR, Chandra S, Sharma SK. Evaluation of 5-aminoisoquinoline (5-AIQ), a novel PARP-1 inhibitor for genotoxicity potential in vitro and in vivo. Toxicol Mech Methods. 2010 Feb;20 (2) :90-5.|[2]Mota-Filipe H, et al. The novel PARP inhibitor 5-aminoisoquinolinone reduces the liver injury caused by ischemia and reperfusion in the rat. Med Sci Monit. 2002 Nov;8 (11) :BR444-53.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, protect from light)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC740326-100 1x 100 µL
Serum Amyloid A (SAA/326), CF740 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC401993-500 1x 500 µL
Cytokeratin 20 (KRT20) (Colorectal Epithelial Marker) (KRT20/1993), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details ![2-[4-[2-(1-Piperidinyl)ethoxy]benzoyl]benzoic Acid](https://cdn.genprice.uk/products/572/4898605990449/imageurl/trc-p482095-250mg.webp)
TRC-P482095-250MG 250 mg
2-[4-[2-(1-Piperidinyl)ethoxy]benzoyl]benzoic Acid
Sign In for Pricing
View Details 
